Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Leukemia, Biphenotypic, Acute 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Meningeal Carcinomatosis 1Lymphoma, Non-Hodgkin 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Hodgkin Disease 1Hematologic Neoplasms 1Hematologic Diseases 1Burkitt Lymphoma 1Blast Crisis 1

Interventions

fludarabine 2Busulfan 2pembrolizumab 1merphos 1itacitinib 1Thiotepa 1Tacrolimus 1Pam2CSK4 acetate and ODN M362 combination 1Methotrexate 1Melphalan 1Lenalidomide 1Imatinib Mesylate 1INCB039110 1Granulocyte Colony-Stimulating Factor 1Cytarabine 1Cyclophosphamide 1Cladribine 1Bone Marrow Transplantation 1Blood Specimen Collection 1AP 1903 reagent 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Hematologic Diseases × merphos × Clear all
NCT04127721 2020-10-29

Itacitinib for the Prevention of Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplantation

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Other hematologic neoplasm

Hematologic Diseases, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡